脐带间充质干细胞输注治疗难治性类风湿关节炎的疗效及安全性初探

目的 探讨脐带间充质干细胞(UC-MSCs)输注治疗难治性类风湿关节炎(RA)的疗效和安全性.方法 2014年12月至2015年11月该院经改善病情抗风湿药(DMARDs)治疗无效的难治性RA住院患者4例,签署知情同意书后予UC-MSCs混悬液静脉榆注1次,细胞数为1×106个/kg.对比输注前后患者关节肿胀压痛数、血沉、C反应蛋白、28个关节痰病活动评分(DAS28)、疼痛视觉模拟评分(VAS)及相关安全性指标.结果 UC-MSCs输注治疗后3名患者关节肿胀压痛数、血沉及DAS28(4)明显改善,另1名患者无效.所有患者均未发生过敏、排斥及其他严重不良反应,血常规肝肾功无异常变化.结论 UC-MSCs输注治疗RA安全性良好,能在一定程度上改善部分难治性RA患者的病情.

Priliminary study on efficacy and safety of umbilical cord mesenchymal stem cells infusion for treating refractory rheumatoid arthritis

Objective To explore the efficacy and safety of umbilical cord mesenchymal stem cells(UC-MSCs) infusion in treating refractory rheumatoid arthritis(RA).Methods Four cases of refractory RA and invalid by improving disease condition and anti-rheumatic drugs in this hospital from December 2014 to November 2015 underwent once UC-MSCs suspension intravenous infusion after signing the informed consent.The cells number was 1 × 106 per kg.We evaluated the tender and swollen joints number,erythrocyte sedimentation rate(ESR),C-reactive protein(CRP),28-joint disease activity score(DAS28),visual analog scale(VAS)pain score and related safety indices were compared between before and after infusion.Results After infusion treatment in 3 cases,the tender and swollen joints number,ESR and DAS28(4) score were significantly improved,but another case was ineffective.No anaphylaxis,rejection reaction or adverse events occurred in all cases and no abnormal change was found in routine blood,liver and kidney function.Conclusion The UC-MSCs infusion is has good safe for treating refractory RA and improves the disease condition to some extent.